Kornimate/medical-research-clean huggingface dataset:
the relationship between needle position and injection pressure during femoral nerve block

Conditions: Orthopedic Disorders

Summary: recent evidence suggests that injection pressure monitoring may be able to predict needle nerve contact in the brachial plexus nerve block model, but little is known about multifascicular nerves. the investigators hypothesize that injection pressure monitoring can reliably predict needle-nerve contact during femoral nerve block.

single center, observational study. patients scheduled for elective lower limb surgery with femoral nerve block will be recruited. femoral nerve will be identified using a linear ultrasound transducer. a 22 ga 5 cm nerve block needle will be inserted with bevel downward and advanced to the following conditions: 1. needle tip slightly indenting the fascia iliaca lateral to the femoral nerve 2. needle tip advanced through fascia iliaca 3. needle tip slightly indenting the anterior surface of the femoral nerve 4. needle tip withdrawn 1 mm from nerve. at each of these conditions, 1 ml of dextrose solution will be injected via an automated pump at 10 ml/min and the spread of injectate observed sonographically. simultaneously, a blinded observer will measure opening injection pressure using both an electronic and a mechanical transducer. if opening pressure reaches 15 psi, this investigator will halt the injection. in addition, minimum threshold current required to elicit a motor response will be recorded for conditions 3 and 4. patients will be contacted at 7 days and asked about any adverse effects.

Eligibility criteria:
inclusion criteria: * age 18-65 * asa physical status i-iii * scheduled for lower limb surgery where femoral block is part of intended analgesic plan exclusion criteria: * contraindication to femoral nerve block (e.g. infection) * bmi \> 35 kg/m2 * inability to communicate postoperative symptoms * pre-existing neurologic deficits in the operative extremity * allergy to local anesthetics * history of opioid dependence

Keywords: opening injection pressure femoral nerve block fascia iliaca ultrasound guided nerve block
autoimmune thyroid disease genetic study

Conditions: Hashimoto's Disease; Graves' Disease

Summary: the hypothesis of this project is that specific genes can be identified that contribute to genetic susceptibility to autoimmune thyroid disease (aitd) in different populations. the specific aim of this project is carry out one or more genomewide association studies (gwas) to map and ultimately identify genes that confer susceptibility to aitd. aitd consists principally of hashimoto's thyroiditis (ht) and graves' disease (gd), characterized clinically generally by hypothyroidism and hyperthyroidism, respectively. both ht and gd are autoimmune diseases characterized by infiltration of the thyroid by t and b cells that are reactive with thyroid antigens and by the production of thyroid autoantibodies (tab). while there is some evidence that there may be genes specific to either gd or ht, other genes appear to be common to both, and some genes may furthermore be in common to susceptibility to other autoimmune diseases. genes known to play a role in aitd include hla, ctla4, thyroglobulin (tg), thsr, and cd40, ptpn2, and ptpn22, several of which are also involved in susceptibility to other autoimmune diseases. all of these genes interact in a complex manner that has yet to be understood. furthermore, it seems clear that relatively few of the genes involved in susceptibility to aitd have thus far been discovered.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of abnormal thyroid function (hypo or hyperthyroidism) due to autoimmune thyroid disease exclusion criteria: * lack of documentation of abnormal thyroid function or clear evidence of autoimmune etiology
a study of zg2001 in participants with kras mutated advanced solid tumours

Conditions: Solid Tumor; KRAS Mutation-Related Tumors

Summary: this study will evaluate the tolerability, safety, effects, and pharmacokinetics of zg2001 in participants with advanced solid tumors that have a kras mutation.


Eligibility criteria:
inclusion criteria: * participants who fully understood this study and voluntarily signed the informed consent form; * men or women ≥ 18 years old; * participants with a kras mutant solid tumor should have progressed on or are ineligible for all therapy(ies) known to confer clinical benefit. * ecog performance status (ps) 0 or 1; * life expectancy \> 3 months. exclusion criteria: * received any sos1 inhibitors; * participants with a known history of hypersensitivity reactions to the ingredients of the preparations used in this study; * other conditions that the investigator considers to be unsuitable for participation in this study.
observational study on treatment of metastatic colorectal cancer and the role of k-ras

Conditions: Metastatic Colorectal Cancer

Summary: the purpose of this study is to describe the treatments received and outcomes of patients with metastatic colorectal cancer, what percentage of these patients have k-ras mutation of the tumor, and to describe the costs of treatments. information will also be collected regarding risk factors, variables among treatment centers and patients, and explorative analyses will be done to try to identify factors that impact prognosis and factors that predict tolerability and response to treatment.


Eligibility criteria:
inclusion criteria: * histologic diagnosis colorectal carcinoma * metastatic disease * signed informed consent exclusion criteria: * prior treatment of metastatic colorectal cancer * refusal or incapability of providing informed consent
cool-ami eu case series clinical study

Conditions: Acute Myocardial Infarction

Summary: a single-center, prospective case series clinical study consecutively enrolling up to 10 patients with expected duration of 12 months or less. the study objectives are to evaluate retention and the feasibility of integrating therapeutic hypothermia using the zoll ivtm system.


Eligibility criteria:
inclusion criteria: * the patient is 18 years of age. * the patient must have symptoms consistent with ami * mi with st-segment elevation * the patient is eligible for pci. * the expected timing of the treatment pathway for the patient will allow for at least 10 minutes of cooling with the ivtm system prior to pci. * the patient or patient legal representative is willing to provide written, informed consent to participate in this clinical study. exclusion criteria: * the patient has had a previous myocardial infarction * the patient is experiencing cardiogenic shock * the patient is experiencing acute pulmonary edema. * the patient is presenting with cardiac arrest. * the patient is presenting with killip risk stratification class ii through iv. * the patient is presenting with atrial fibrillation. * the patient has a history of a prior large myocardial infarct or an infarct in the same segment that is currently affected. * the patient requires an immediate surgical or procedural intervention other than pci * the patient has an aortic dissection. * the patient has hepatic failure. * the patient has end stage kidney disease. * the patient is febrile * known chronic congestive heart failure (chf). * known previous cabg. * known recent stroke * cardio-pulmonary decompensation that has occurred en route to the hospital * contraindications to hypothermia * the patient has a known hypersensitivity or contraindication to aspirin, heparin, or sensitivity to contrast media, which cannot be adequately pre-medicated. * the patient has a known history of coagulopathy * the patient is known to be pregnant * the patient has a known hypersensitivity to antishivering medications. * patient has a known history of severe hepatic or renal impairment. * the patient has an inferior vena cava filter in place (ivc). * the patient has a life expectancy of less than 1 year * the patient has a known, unresolved history of drug use * the patient is currently enrolled another investigational drug or device trial

Keywords: hypothermia acute myocardial infarction percutaneous coronary intervention ami pci therapeutic hypothermia
a study of intravenous vrt106 for locally advanced or metastatic solid tumors

Conditions: Solid Tumors

Summary: a phase i study of the safety and tolerability of vrt106 administered intravenously for treatment of patients with locally advanced or metastaticsolid tumors

to evaluate vrt106 for injection in patients with locally advanced/metastatic solid tumours for safety and tolerability, exploring the maximum tolerated dose (mtd)/maximum administered dose (mad)/optimal bioavailable dose (obd) and/or the recommended phase ii clinical dose (rp2d) to provide a recommended dose for subsequent clinical trials.

Eligibility criteria:
inclusion criteria: 1. subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the icf; and are willing to follow and have the ability to complete all trial procedures. 2. males and females are aged at 18-75 years (including borderline values) at the time of signing the icf, male or female. 3. subjects are histologically or cytologically confirmed to be intolerable or refractory to the standard systemic treatment. 4. subjects have at least one measurable lesion. 5. ecog score of 0 to 28 days prior to first dose of imp. 6. an expected survival time of ≥ 12 weeks. 7. have sufficient organ function. 8. female patients of childbearing potential with a negative serum pregnancy test within 7 days prior to first dose of study drug. 9. subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose. exclusion criteria: 1. subject has received any antitumor therapy within 4 weeks prior to the first dose of imp. 2. subject has previously received oncolytic virus or other gene drug therapy. 3. subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of imp. 4. subject is known to have an allergic reaction to any of the components of imp. 5. women who are breastfeeding.

Keywords: solid tumor oncolytic virus vrt106
a study of plm60 in subjects with relapsed small-cell lung cancer after platinum-based first-line chemotherapy

Conditions: Small Cell Lung Cancer

Summary: this is an open, multicenter phase ii clinical study for plm60. the primary aim of the study is to observe the initial efficacy of plm60 in treatment of small cell lung cancer. the secondary aim is to explore the safety and pk characteristics of plm60


Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of sclc; 2. must have recurrence or progression after platinum-based first-line chemotherapy or chemoradiation therapy for the treatment of sclc; 3. ecog performance status 0\~2; 4. measurable lesion according to recist v1.1; 5. life expectancy ≥ 12 weeks; 6. adequate organ function; 7. signed informed consent from the patient. exclusion criteria: 1. radical surgical treatment for primary small cell lung cancer; 2. any anti-tumor treatment received within 4 weeks before the first use of the study drug; 3. untreated or symptomatic central nervous system (cns) metastases; 4. uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; 5. history of serious systemic diseases; 6. history of serious autoimmune diseases; 7. those receiving treatment of adriamycin or other anthracyclines previously, with the total cumulative adriamycin (or adriamycin-equivalent) dose of \>360 mg/m2.
effects of an interdisciplinary fitness and social engagement intervention

Conditions: TBI (Traumatic Brain Injury)

Summary: this study will evaluate feasibility and preliminary effectiveness of a 10-week interdisciplinary and multimodal intervention that utilizes patient education, group discussion, and supervised exercise for veterans with a history of traumatic brain injury (tbi). primary outcomes include physical activity (pa), sleep quality, and community integration.

this randomized controlled trial will have a sample size of 24. veterans between the ages of 18 and 65 in the polytrauma and tbi program who are greater than 1 year post injury prior to entering the study, will be recruited. after randomization participants in the intervention group will complete a 10 week bout of multidisciplinary wellness education, group discussion, and supervised exercise. the intervention will occur weekly and last up to 2 hours. the control group will complete a 10week comprehensive health education program simultaneously. all measures will be collected again, post intervention. a follow-up collection will occur at 3 months post-intervention.

Eligibility criteria:
inclusion criteria: * tbi of at least mild severity using criteria related to disturbance of consciousness * most recent tbi occurred \>1 year prior to consent process * medically stable with physician approval to participate exclusion criteria: * unable to provide informed consent and no proxy available * prior history of known bipolar disorder or schizophrenia or severe psychiatric illness * veterans with any cardiac condition that may cause sudden decompensation during cardiovascular testing and training (e.g., severe congestive heart failure and uncontrolled hypertension) * veteran is currently active in a skilled physical therapy program. * veterans who meet or exceed american heart association and american college of sports medicine guidelines for physical activity

Keywords: social engagement physical activity sleep quality traumatic brain injury veteran
the effect of 40 hz transcranial stimulation on the incidence of emergence delirium in children

Conditions: Emergence Delirium; Anesthesia; Children

Summary: emergence delirium is a complex of perceptual deficits and psychomotor agitation most commonly seen in preschool children in the early post-anesthetic period. it increases the risk of bed falls, accidental catheter removal, surgical wound dehiscence, and delayed discharge in children. exogenous 40 hz stimulation can improve cognitive functioning. therefore, the aim of this study was to explore the effect of 40hz stimulation on the incidence of emergence delirium in children undergoing vascular malformation surgery under sevoflurane anesthesia.


Eligibility criteria:
inclusion criteria: 1. age 3-14 years old 2. asa classification i or ii 3. proposed vascular malformation surgery under sevoflurane general anesthesia 4. anesthesia duration\>1h 5. obtaining informed consent exclusion criteria: 1. emergency surgery 2. mental retardation 3. neurological disorders with manic-like symptoms 4. presence of severe kidney or liver disease, heart or respiratory disease 5. autoimmune diseases 6. vascular malformation of the head and face 7. significant life changes in the 1 month prior to surgery
modified tip (snodgrass) using interrupted sutures in hypospadias

Conditions: Hypospadias

Summary: using interrupted sutures in tip technique by snodgrass in repair of hypospadias instead of continuous sutures


Eligibility criteria:
inclusion criteria: * midshaft , distal , * coronal hypospadias exclusion criteria: -
adjusting challenge-skill balance to improve the elderly's quality of life

Conditions: Elderly

Summary: the purpose of this study was to clarify the effects on health-related qol of occupational therapy involving the adjustment of challenge-skill balance in the activity of elderly clients.

this study was single-blind, randomized controlled trial. clients were randomly assigned by blocked randomization (block size 4) to either the experimental group (occupational therapy that included assessment and adjustment of the challenge-skill balance of the activities) or to the control group (occupational therapy as normally conducted at the day care center). randomization was stratified by sex and euroqol visual analogue scale, resulting in four layers. the primary outcome was change in health-related quality of life after 10 sessions of occupational therapy. clients were assessed before the intervention (pre-test) and after the 10th session (post-test). significant differences were observed in the euroqol-5 dimension (eq-5d) score and in the medical outcome study 8-item short-form health survey (sf-8) scores for general health, physical functioning , and vitality.

Eligibility criteria:
inclusion criteria: * age \>60 years * occupational therapy at the center for \>3 months exclusion criteria: * dementia * visual impairment

Keywords: occupational therapy quality of life
effects of milk proteins on protein synthesis in healthy male subjects fed a hypercaloric, high sucrose diet

Conditions: Obesity

Summary: this study aims at assessing the hypothesis that dietary protein content is a major factor regulating lean body mass gain and energy expenditure during overfeeding, and thus long term body weight gain to test this hypothesis, healthy normal weight male and female subjects will before and after a 7-day hypercaloric, high-sucrose diet (+40% excess energy as sucrose) and either a low (5% total energy) or a high (20% total energy) protein intake. each subject will be studied with both low- and high protein diets according to a randomized, crossover study. on each occasion the following measurements will be done in basal conditions (after 2-day isoenergetic, controled diet) and at the end of the 7-day overfeeding: * whole-body protein turnover, oxidation and synthesis in fasting conditions and fed conditions (13c-labelled leucine) * intrahepatic and intramuscular fat concentration (1h-magnetic resonance spectroscopy) * energy metabolism in fasted and fed conditions (indirect calorimetry) * plasma concentration of glucose, non-esterified fatty acids, total triglyceride, very-low density lipoprotein (vldl)-triglyceride, insulin, glucagon, growth hormone (gh), insulin-like growth factor 1 (igf1), insulin-like growth factor binding protein (igfbp) 1,2 and 3 in fasting and fed conditions the effects of high-protein and low-protein sucrose overfeeding on whole body protein synthesis will be compared using two-way anova; relationships between changes in whole body protein synthesis on one hand, and intrahepatic/intramuscular fat concentrations, total energy expenditure, and plasma concentration of metabolic variables on the other hand, will be evaluated by linear regression analysis


Eligibility criteria:
inclusion criteria: * good apparent health * low physical activity * non-smokers exclusion criteria: * vegans or following any special diet * consumption of \> 3 dl/day sweetened beverages * changes in body \> +/- 3kg over the past 3 months * contra-indications to magnetic resonance spectroscopy * drug or substance abuse * consumption \> 10g/day alcohol * lactose intolerance

Keywords: protein synthesis intrahepatic fat lean body mass igf1 energy metabolism
peers plus mobile app for treatment in hiv

Conditions: Human Immunodeficiency Virus

Summary: this study called "peers plus mobile app for treatment in hiv (path)" is a two-arm randomized controlled trial (rct) evaluating the efficacy of an intervention that combines peer navigation and mobile health (mhealth) technology to support hiv care outcomes among hispanic and black persons living with hiv (hbplh).

path is a community-academic collaboration with a federally qualified health center serving patients in south san diego under the ryan white model of care. the scientific premise of this rct is that combining two interventions developed by this team (peer navigation + mhealth) into a single mhealth peer navigation intervention (path) will eliminate the need for in-person support from peer navigators, promote high impact on hiv care continuum outcomes, as well as extend broader reach to underserved communities. the rct will test the efficacy of path with 375 hbplh (among whom \>33% will report stimulant and/or opioid use in the past 6 months). aim 1. improve the primary outcomes - sustained viral suppression (i.e., suppressed viral load at both 6- and 12-month follow-up), and secondary outcomes (e.g., retention in care) compared to usual care. sub-aim 1: explore subgroup differences in efficacy based on factors like race/ethnicity and substance use. aim 2. examine the theory-informed mediators (e.g., self-efficacy to engage in hiv care, hiv stigma) through which path has the greatest impact on sustained viral suppression among hbplh. aim 3. explore whether path significantly affects substance-related outcomes (e.g., frequency of substance use, engagement in substance abuse treatment) when compared to usual care among those using substances (i.e., stimulants and/or opioids).

Eligibility criteria:
inclusion criteria: * ≥18 years old * can read and speak english or spanish * self-reported diagnosis of hiv by a physician or healthcare provider * currently prescribed hiv medication * having access to an internet browser on a home computer, tablet, or smart phone * does not plan to move out of the san diego area in the next 12 months * meets one or more of the following medical chart verified or self-reported criteria * one or more detectable viral load test result (\>200 copies m/l) in the past 12-months while on antiretroviral therapy for at least 3 months * having missed 1 or more scheduled hiv care appointments in the last 12 months * last hiv care visit was more than 6 months ago * self-reporting less than 90% antiretroviral therapy adherence in the last 4 weeks using the wilson-3 scale * report stimulant or opioid use (non-prescription) in the past 6 months exclusion criteria: * \<18 years old * currently enrolled in any program, intervention, or research study designed to improve antiretroviral therapy adherence or engagement in hiv care (e.g., linkpositively) * members of one of the community advisory boards providing advisement on the study.

Keywords: hiv telemedicine substance use